Phase II trial of merbarone in soft tissue sarcoma. A Southwest Oncology Group study
- PMID: 1487411
- DOI: 10.1007/BF00944194
Phase II trial of merbarone in soft tissue sarcoma. A Southwest Oncology Group study
Abstract
Thirty-seven patients with advanced soft tissue sarcoma were treated with merbarone utilizing a daily intravenous schedule for five days. Only one partial response was observed in the thirty-three evaluable patients. The major toxicities were renal, with elevation of creatinine and/or proteinuria, and gastrointestinal, with mild to moderate nausea and vomiting. Merbarone in this dose and schedule has minimal activity in soft tissue sarcoma.
Similar articles
-
Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma. A Southwest Oncology Group study.Invest New Drugs. 1995;13(2):143-7. doi: 10.1007/BF00872863. Invest New Drugs. 1995. PMID: 8617577 Clinical Trial.
-
Phase II trial of merbarone in pancreatic carcinoma. A Southwest Oncology Group study.Am J Clin Oncol. 1993 Aug;16(4):327-8. doi: 10.1097/00000421-199308000-00010. Am J Clin Oncol. 1993. PMID: 8328410 Clinical Trial.
-
Phase II evaluation of merbarone in renal cell carcinoma.Invest New Drugs. 1994;12(2):147-9. doi: 10.1007/BF00874446. Invest New Drugs. 1994. PMID: 7860233 Clinical Trial.
-
Merbarone: an antitumor agent entering clinical trials.Invest New Drugs. 1987;5(2):137-43. doi: 10.1007/BF00203538. Invest New Drugs. 1987. PMID: 3308762 Review.
-
Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.Future Oncol. 2015;11(11 Suppl):3-14. doi: 10.2217/fon.15.78. Future Oncol. 2015. PMID: 26043310 Review.
Cited by
-
Hepatoma/merbarone. A Southwest Oncology Group study.Invest New Drugs. 1994;12(4):337-40. doi: 10.1007/BF00873051. Invest New Drugs. 1994. PMID: 7775137 Clinical Trial.
-
Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma. A Southwest Oncology Group study.Invest New Drugs. 1995;13(2):143-7. doi: 10.1007/BF00872863. Invest New Drugs. 1995. PMID: 8617577 Clinical Trial.
-
The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy.Pharmaceuticals (Basel). 2023 Jan 9;16(1):94. doi: 10.3390/ph16010094. Pharmaceuticals (Basel). 2023. PMID: 36678591 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical